

May 18, 2017

Sumitomo Dainippon Pharma Co., Ltd.

**Sumitomo Dainippon Pharma announces the Clinical Data  
will be presented at ASCO 2017**

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) announced today that a total of 12 presentations including clinical data for investigational anti-cancer agents napabucasin (BBI608), amcasertib (BBI503) and WT2725 will be presented at the poster session of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2 to June 6, 2017.

**Napabucasin: Study results, 7 presentations**

Abstract number	Title of poster presentation	Date and Time, Location	Study number	Cancer Type
<a href="#">9052</a>	A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated non-squamous non-small cell lung cancer.	June 3, 2017 8:00 AM-11:30 AM (local time), Hall A	201 Study: NCT01325441	Non-small cell lung cancer
<a href="#">3529</a>	Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).	June 3, 2017 8:00 AM-11:30 AM (local time), Hall A	246 Study: NCT02024607	Colorectal cancer
<a href="#">4106</a>	A phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).	June 3, 2017 8:00 AM-11:30 AM (local time), Hall A	118 Study: NCT02231723	Pancreatic cancer
<a href="#">5548</a>	A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated platinum resistant ovarian cancer.	June 3, 2017 1:15 PM-4:45 PM (local time), Hall A	201 Study: NCT01325441	Ovarian Cancer
<a href="#">9553</a>	A phase 1b study of napabucasin plus weekly paclitaxel in patients with advanced melanoma.	June 3, 2017 1:15 PM-4:45 PM (local time), Hall A	201 Study: NCT01325441	Melanoma

<a href="#">1084</a>	A phase 2 study of napabucasin with weekly paclitaxel in previously treated metastatic breast cancer.	June 4, 2017 8:00 AM-11:30 AM (local time) , Hall A	201 Study: NCT01325441	Breast cancer
<a href="#">4077</a>	BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC).	June 3, 2017 8:00 AM-11:30 AM (local time) , Hall A	BBI HCC 103 Study: NCT02279719	Hepato-cellular carcinoma

#### Napabucasin: Study design, 2 presentations

Abstract number	Title of poster presentation	Date and Time, Location	Study number	Cancer Type
<a href="#">TPS3619</a>	CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).	June 3, 2017 8:00 AM-11:30 AM (local time) , Hall A	CanStem303C Study: NCT02753127	Colorectal cancer
<a href="#">TPS4148</a>	CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC).	June 3, 2017 8:00 AM-11:30 AM (local time) , Hall A	CanStem111P Study: NCT02993731	Pancreatic cancer

#### Amcasertib: Study results, 2 presentations

Abstract number	Title of poster presentation	Date and Time, Location	Study number	Cancer Type
<a href="#">6032</a>	A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor in advanced head and neck cancer.	June 5, 2017 1:15 PM-4:45 PM (local time) , Hall A	101 Study: NCT01781455	Head and Neck cancer
<a href="#">6036</a>	A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor, in advanced adenoid cystic carcinoma.	June 5, 2017 1:15 PM-4:45 PM (local time), Hall A	101 Study: NCT01781455	Adenoid Cystic Carcinoma

WT2725: Study results, 1 presentation

Abstract number	Title of poster presentation	Date and Time, Location	Study number	Cancer Type
<a href="#">2066</a>	Initial phase 1 study of WT2725 dosing emulsion in patients with advanced malignancies.	June 5, 2017 1:15 PM-4:45 PM (local time), Hall A	D8350004Study : NCT01621542	Solid tumors, Hematologic malignancies

\*The abstract is now available on the official website of ASCO. There is the link to applicable abstract on abstract number of each study.

(Reference)

**【About napabucasin:BBI608】**

Napabucasin is an investigational first-in-class anti-cancer agent created by Boston Biomedical, Inc., wholly-owned subsidiary of Sumitomo Dainippon Pharma. Napabucasin is an orally-administered small molecule agent with a novel mechanism of action designed to inhibit cancer stemness pathways by targeting STAT3.

**【About amcasertib:BBI503】**

Amcasertib is an investigational anti-cancer agent created by Boston Biomedical, Inc. Amcasertib is an orally-administered small molecule agent with a novel mechanism of action designed to inhibit cancer stemness pathways, including Nanog, by targeting stemness kinases.

**【About WT2725】**

WT2725 is an investigational therapeutic cancer peptide vaccine derived from Wilms' tumor gene 1 (WT1) protein. WT2725 is expected to treat various types of hematologic malignancies and solid tumors that express WT1, by inducing WT1-specific cytotoxic T-lymphocytes that attack WT1-expressing cancer cells.

Contact:

Public Relations/Investor Relations

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407(Osaka)

+81-3-5159-3300 (Tokyo)